Company Profile
Based in Arizona, Electromedical Technologies Inc. (EMED) specializes in bioelectronics with an eye toward pain control remedies. Originally founded in 2002, the company has been committed to creating bioelectronic devices utilizing frequency, vibration, and energy to reduce both acute and chronic pain. For patients with different painful disorders, these devices provide a non-invasive substitute and augment current medical treatments.
Leadership Team
Matthew Wolfson, CEO & CFO
Establishing Electromedical Technologies in 2002, Matthew Wolfson oversaw Wellness Pro series research and development. Along with co-founding Globalcom 2000, one of the biggest phone card companies in the United States, and One World Communications, an international callback company with more than 150 training centers all around, Wolfson's entrepreneurial path also includes EMED's expansion and creativity in the bioelectronic market have been greatly aided by his broad knowledge in technology and business.
Dos Sarbassov, Ph.D. – Lead Scientific Advisor
Experienced in cell-signaling, Dr. Dos Sarbassov focuses on cancer research and control of cell growth. After earning his Ph.D. from the University of Arkansas for Medical Sciences, he worked postdoctoral at MIT's Whitehead Institute for Biomedanical Research. His background consists in major contributions to the research of m TOR complexes at the University of Texas MD Anderson Cancer Center and Weill Cornell School of Medicine. Advancement of EMED's bioelectronic technologies depends much on Sarbassov's thorough knowledge of cellular biology.
Alexander A. Pedenko, MD – Chief Medical Advisor
Leading EMED's medical advisory team is board-certified anesthesiologist Dr. Alexander Pedkenko, who has more than 20 years of experience in anesthesia and pain management. In addition to founding Premier Anesthesia Consultants and serving as a clinical instructor and assistant professor of anesthesiology at Penn State University, he is the president of His clinical knowledge is essential in directing the creation of EMED's medical equipment to guarantee they satisfy the best criteria of patient care.
Constantin Kishkovski – European Business Development
Constantin Kishkovski supervises European business development initiatives for EMED. He has led Johnson & Johnson's representative office in Ukraine and Moldova and brought Nestle branded goods to the Ukrainian market. In addition, Kishkovski started and oversees KeyWord Group, a top corporate support company in Ukraine and CIS. Extensive knowledge in corporate strategy and market expansion is absolutely essential for EMED to be widely spread over Europe.
Petar Gajic – Director of Technology
EMED's technology and quality control is handled by Petar Gajic, over 25 years of experience in computer systems and networks. Gajic, a certified Google Cybersecurity Professional and Microsoft System Engineer, supervises the creation of new products and controls the Quality Management System (QMS) of the business to guarantee that every product satisfies ISO 13485:2016 criteria. His experience guarantees that EMED's equipment is dependable and technologically advanced.
Recent Strategic Developments
Sales Growth and Financial Performance
Driven by great demand for its creative medical devices, EMED saw a solid 17% rise in income for the year ended 2023 compared to 2022. This expansion is a reflection of EMED's strategic initiatives' success as well as of its products' rising market acceptance. The company also effectively renegotiated creditor agreements, which improved its financial situation. These developments strengthen the basis of EMED and offer a strong stage for future development and creativity.
Strategic Partnership with Lionheart Health
EMED has taken a major strategic step by teamed with medical aesthetics and longevity solution provider Lionheart Health. This cooperation is evidence of the congruence of the goals of both companies to challenge the limits of wellness and health technology. Among industry honors for Lionheart Health are the esteemed Abbvie Allergen Aesthetics ULP Golden Passport Award. Moreover, Lionheart Health's participation in the $101 million XPRIZE contest for healthspan extension emphasizes their dedication to trailblazing developments in aging and wellness.
The Wellness Pro InfinityTM device from EMED should be much more widely available thanks to this collaboration. This partnership guarantees wide access to EMED's innovative technology as all 124 Lionheart Longevity & Wellness MedSpa sites set to feature the Wellness Pro InfinityTM. This integration will offer a larger audience non-invasive, drug-free pain management options, so improving EMED's visibility in the markets for medical aesthetics and longevity.
Wellness Pro Infinity™ Development
EMED proudly declared that the Wellness Pro InfinityTM development had been successfully completed, so attesting to the company's dedication to forward bioelectronic medical devices. The tool boasts the innovative Digital Synthesis system and EMED's own iDNA technology. These developments offer unparalleled technical capability and accuracy, so representing a major advance in electrotherapy. Notwithstanding obstacles including European plastic manufacturing delays, EMED's engineering team responded fast to guarantee the best manufacturing partner and the highest quality standards.
For upscale electrotherapy equipment, the Wellness Pro InfinityTM is likely to establish a new industry benchmark. Its sophisticated technology improves therapy efficacy and meets unmet clinical needs, so providing better results for patients. Establishing EMED as a leader in the bioelectronic medicine market, this gadget is expected to completely change the way doctors approach patient treatment.
Market Expansion and Sales Strategy
EMED has hired a medical group consisting of 200 professional medical device sales representatives in order to take advantage of the momentum created by its recent innovations. These seasoned sales representatives will present the Wellness Pro InfinityTM to a large network of clinics, hospitals, and doctors all around the United States. This calculated expansion is expected to generate notable sales increase, so improving EMED's whole financial performance and preparing the business for a good year's ending.
Recent Stock Performance
Stock performance of Electromedical Technologies Inc. has displayed notable volatility. According to most recent figures, the stock is trading at $0.00140. The stock price has risen 180% during the past week and month. The stock has increased by 40% year over year as well as year to-date. The stock dropped 97.74% over the past three years and 99.54% over the past five years, indicating a declining longer-term performance though. These numbers underline the volatility of the stock and the possible hazards for investors even with the recent increases.
Technically, the indicators of the stock show an EMA (1 D) of 15.99, a MACD (1 D) of -0.05, an RSI (1 D) of 49.06, a SMA (1 D) of 15.94, and a VWAP (1 D) of 0.0. These indicators reveal the present trading momentum of the stock and help to understand its short-term patterns.
Conclusion
By means of its creative bioelectronic devices, Electromedical Technologies Inc. is poised to have a major influence on the healthcare sector. Strong leadership of the company, strategic alliances, and modern technology have set the stage for upcoming success. EMED's recent financial successes and product innovations point to a bright future even if its stock performance is erratic. EMED is dedicated to provide non-invasive pain management solutions that raise patient quality of life worldwide as it keeps growing its market presence and enhancing its product offers.
For more information about Electromedical Technologies, visit https://electromedtech.com/.
